Recent Finacing
Recent Raise
DNAtrix is a clinical-stage biotech developing genetically modified oncolytic adenoviruses, advancing lead candidate DNX-2401 in clinical trials—including Phase Ib combination studies with temozolomide—for recurrent glioblastoma.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors